Jointown Pharma announced that the new drug application for Kangtaiatinib granules, a single drug developed independently by the company, for the treatment of locally advanced or metastatic non-small cell lung cancer patients with anaplastic lymphoma kinase positivity has been accepted by the National Medical Products Administration.
首药控股：康太替尼颗粒新药上市申请获受理
Jointown Pharma: The new drug application for Kangtaiatinib granules has been accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated